Mirum Pharma (MIRM) - Gross Margin

MIRM (Mirum Pharmaceuticals, Inc.) - company brandmark

Mirum Pharmaceuticals maintains a resilient business driven by sales growth, despite its reliance on a narrow range of orphan drugs. Gross margin fluctuations on GURU.Markets capture the current trend, with the value fixed at 81.60. Profitability is based on the commercialization of innovative antipruritic drugs for genetic liver pathologies. Drug development relies on an academic approach and the involvement of leading research scientists.

mirumpharma.com (MIRM): Return on Gross Profit from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for Mirum Pharmaceuticals (MIRM)

- stock price and consensus target price:
- market capitalization indicators:
Fundamental valuation:Mirum Pharmaceuticals
Product sample of Mirum Pharmaceuticals Inc

The high efficiency of implementing innovative drugs for the treatment of rare liver pathologies provides Mirum Pharmaceuticals (MIRM) with significant operating leverage. By analyzing the gross margin structure on the GURU.Markets platform, an investor assesses the revenue share net of direct production costs, which allows for the determination of the business's fundamental ability to generate profit and confirms the long-term sustainability of the asset's market quotes.